ALX2004 starts phase 1, along with the sixth oncology-focused in vivo Car-T.
ApexOnco Front Page
Recent articles
If Pfizer hands back the estrogen receptor degrader, Arvinas will seek a new partner.
A look at big oncology deals since 2016 suggests that there have been more duds than successes.
Work targeting mesothelin, and some other antigens that have hitherto disappointed, continues.
The group has approval for Amtagvi, but now faces the prospect of a solo launch.
Approval on the basis of Flaura2 is part of a double success for Astra's Tagrisso, which has also scored in Laura.
GSK’s Zejula win is the latest chapter in a long and convoluted history of PARP inhibition.
Lifileucel heads up the list of upcoming US FDA catalysts.